← Leaderboards
Florea Lupu
Oklahoma Medical Research Foundation
$19,062,937
Attributed
$25,390,049
Total exposure
19
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,390,049 · 19
By mechanism
R01$15,994,589 · 8
U19$4,414,940 · 2
P30$2,272,256 · 1
RC1$1,000,000 · 1
P20$737,326 · 5
S10$500,000 · 1
Top collaborators
- Owen J Mccarty10 shared
- John D Lambris4 shared
- Alan Jackson Tackett4 shared
- George A. Calin3 shared
- Sai-Ching Jim Yeung3 shared
- Kenneth Mark Coggeshall2 shared
- Charles T Esmon2 shared
- Gary Kinasewitz2 shared
Most similar at Oklahoma Medical Research Foundation
Same institution · by research overlap
- Charles T Esmon$7,886,182
- Gary Kinasewitz$333,333
Others in their field
Top investigators on “Sepsis”
- Ian A Wilson · Scripps Research Institute, The$50,300,809
- Vance G Fowler · Duke University$48,391,331
- Alon Singer · Helixbind, Inc.$39,385,728
- Henry F Chambers · Duke University$39,317,414
- Jonathan Michael Dean · University Of Utah$36,397,260
- Rama K Mallampalli · Ohio State University$23,779,171
Research focus
SepsisFunctional DisorderPathogenPapioAnimalsInfectionTissuesOrganResponsePlayInflammatory ResponseCessation Of LifeAnimal ModelEscherichia ColiCoagulation ProcessPathogenesisMolecularEffective TherapyInflammationNovel TherapeuticsLifePreventNonhuman PrimateLead
Grant awards (59)
Complement C5 inhibition as sepsis therapy$633,416
R01 · FY2025 · AI · contact PI
Complement C5 inhibition as sepsis therapy$633,416
R01 · FY2024 · AI · contact PI
Contact Activation and Infection$553,057
R01 · FY2024 · AI
Discovery and Characterization of Novel Sepsis Proteome Biomarkers$535,585
R01 · FY2024 · GM · contact PI
Complement C5 inhibition as sepsis therapy$633,416
R01 · FY2023 · AI · contact PI
Contact Activation and Infection$553,057
R01 · FY2023 · AI
Discovery and Characterization of Novel Sepsis Proteome Biomarkers$535,585
R01 · FY2023 · GM · contact PI
Contact Activation and Infection$790,401
R01 · FY2022 · AI
Complement C5 inhibition as sepsis therapy$633,416
R01 · FY2022 · AI · contact PI
Discovery and Characterization of Novel Sepsis Proteome Biomarkers$535,585
R01 · FY2022 · GM · contact PI
Animal Model Core$591,743
U19 · FY2021 · AI · contact PI
Discovery and Characterization of Novel Sepsis Proteome Biomarkers$554,285
R01 · FY2021 · GM · contact PI
Contact Activation and Infection$526,039
R01 · FY2021 · AI
Contact Activation and Infection$838,128
R01 · FY2020 · AI
Animal Model Core$593,667
U19 · FY2020 · AI · contact PI
Microscopy Core$457,125
P30 · FY2020 · GM · contact PI
Coagulation and Complement Activation in Sepsis$421,095
R01 · FY2020 · GM · contact PI
Viral miRs and cellular miRs in sepsis$354,598
R01 · FY2020 · GM
Animal Model Core$610,443
U19 · FY2019 · AI · contact PI
Microscopy Core$457,125
P30 · FY2019 · GM · contact PI
Coagulation and Complement Activation in Sepsis$421,095
R01 · FY2019 · GM · contact PI
Viral miRs and cellular miRs in sepsis$354,598
R01 · FY2019 · GM
Animal Model Core$559,359
U19 · FY2018 · AI · contact PI
Microscopy Core$457,125
P30 · FY2018 · GM · contact PI
FXI and Sepsis$430,481
R01 · FY2018 · GM
Viral miRs and cellular miRs in sepsis$369,598
R01 · FY2018 · GM
Coagulation and Complement Activation in Sepsis$349,000
R01 · FY2018 · GM · contact PI
FXI and Sepsis$127,988
R01 · FY2018 · GM
Coagulation and Complement Activation in Sepsis$72,095
R01 · FY2018 · GM · contact PI
Animal Model Core$544,301
U19 · FY2017 · AI · contact PI
Microscopy Core$443,756
P30 · FY2017 · GM · contact PI
FXI and Sepsis$438,798
R01 · FY2017 · GM
Coagulation and Complement Activation in Sepsis$349,000
R01 · FY2017 · GM · contact PI
Animal Model Core$472,966
U19 · FY2016 · AI · contact PI
Microscopy Core$457,125
P30 · FY2016 · GM · contact PI
FXI and Sepsis$447,726
R01 · FY2016 · GM
Animal Model Core$536,240
U19 · FY2015 · AI · contact PI
FXI and Sepsis$479,181
R01 · FY2015 · GM
Development of a mouse model of peptidoglycan-induced pathology$214,375
R21 · FY2015 · AI
Complement inhibition as sepsis therapy$521,055
R01 · FY2014 · GM · contact PI
Animal Model Core$506,221
U19 · FY2014 · AI · contact PI
Development of a mouse model of peptidoglycan-induced pathology$256,563
R21 · FY2014 · AI
Complement inhibition as sepsis therapy$502,824
R01 · FY2013 · GM · contact PI
Complement inhibition as sepsis therapy$506,560
R01 · FY2012 · GM · contact PI
Complement inhibition as sepsis therapy$535,225
R01 · FY2011 · GM · contact PI
MICROSCOPY$200,489
P20 · FY2011 · RR · contact PI
Validation of extracellular histones as biomarker and therapeutic target in sepsi$500,000
RC1 · FY2010 · GM · contact PI
Intravital Multiphoton Microscope$500,000
S10 · FY2010 · RR · contact PI
COBRE: OK MED RES FOUND: CORE I: IN VITRO MICROSCOPY CORE$130,019
P20 · FY2010 · RR · contact PI
Validation of extracellular histones as biomarker and therapeutic target in sepsi$500,000
RC1 · FY2009 · GM · contact PI
EPCR, TAFI as Regulators of PMN/Endothelial Interaction$92,499
R01 · FY2009 · GM · contact PI
EPCR, TAFI as Regulators of PMN/Endothelial Interaction$319,647
R01 · FY2007 · GM · contact PI
COBRE: OK MED RES FOUND: CORE I: IN VITRO MICROSCOPY CORE$100,540
P20 · FY2007 · RR · contact PI
EPCR, TAFI as Regulators of PMN/Endothelial Interaction$319,649
R01 · FY2006 · GM · contact PI
COBRE: OK MED RES FOUND: CORE I: IN VITRO MICROSCOPY CORE$105,536
P20 · FY2006 · RR · contact PI
EPCR, TAFI as Regulators of PMN/Endothelial Interaction$317,853
R01 · FY2005 · GM
COBRE: OK MED RES FOUND: CORE I: IN VITRO MICROSCOPY CORE$104,374
P20 · FY2005 · RR
EPCR, TAFI as Regulators of PMN/Endothelial Interaction$308,638
R01 · FY2004 · GM
CORE--IN VITRO MICROSCOPY$96,368
P20 · FY2004 · RR